Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Published:2019-10 Issue:4 Volume:36 Page:431-443.e5
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Eide Christopher A.,Zabriskie Matthew S.,Savage Stevens Samantha L.,Antelope Orlando,Vellore Nadeem A.,Than Hein,Schultz Anna Reister,Clair Phillip,Bowler Amber D.,Pomicter Anthony D.,Yan Dongqing,Senina Anna V.,Qiang Wang,Kelley Todd W.,Szankasi Philippe,Heinrich Michael C.,Tyner Jeffrey W.,Rea Delphine,Cayuela Jean-Michel,Kim Dong-Wook,Tognon Cristina E.,O'Hare Thomas,Druker Brian J.,Deininger Michael W.

Funder

Huntsman Cancer Institute

VA Merit Review

Leukemia & Lymphoma Society

NIH

Howard Hughes Medical Institute

Bristol-Myers Squibb

Celgene

Novartis

Gilead

Aileron Therapeutics

ALLCRON

Cepheid

Gilead Sciences

Vivid Biosciences

Baxalta

Aptose Biosciences

Blueprint Medicines

Beta Cat

GRAIL

Third Coast Therapeutics

CTI BioPharma

MolecularMD

Amgen

Burroughs Wellcome Fund

CureOne

Beat AML LLS

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference40 articles.

1. Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an n-ethyl-n-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations;Bradeen;Blood,2006

2. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion;Breccia;Ann. Hematol.,2017

3. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity;Corbin;J. Clin. Invest.,2011

4. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors;Corbin;Cancer Res.,2013

5. Ponatinib in refractory Philadelphia chromosome-positive leukemias;Cortes;N. Engl. J. Med.,2012

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs;ChemBioChem;2024-09-12

2. A Novel Next-Generation Sequencing Assay for the Identification of BCR::ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations;The Journal of Applied Laboratory Medicine;2024-09-03

3. Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia;Oncohematology;2024-09-01

4. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy;Cancer Cell;2024-09

5. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy;Blood;2024-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3